Celcuity Inc

CELC

Company Profile

  • Business description

    Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

  • Contact

    16305 36th Avenue North
    Suite 100
    MinneapolisMN55446
    USA

    T: +1 763 392-0767

    E: [email protected]

    https://www.celcuity.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    87

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,772.001.00-0.01%
CAC 407,636.1029.81-0.39%
DAX 4023,853.0756.54-0.24%
Dow JONES (US)44,094.77275.500.63%
FTSE 1008,754.136.83-0.08%
HKSE24,072.28211.87-0.87%
NASDAQ20,369.7396.270.47%
Nikkei 22539,986.33501.06-1.24%
NZX 50 Index12,734.53131.711.05%
S&P 5006,204.9531.880.52%
S&P/ASX 2008,541.101.20-0.01%
SSE Composite Index3,444.4320.200.59%

Market Movers